Akari Therapeutics Plc ADR Dossier
Qualitative Analysis
Business overview
Akari Therapeutics Plc (Nasdaq: AKTX) is an oncology-focused biotechnology company specializing in the discovery, research, and development of next-generation precision antibody-drug conjugates (ADCs). Following its transformational merger with Peak Bio Inc. in November 2024, Akari shifted its strategic focus from legacy autoimmune and inflammatory programs to oncology and its proprietary ADC platform. The company's core technology centers on its novel, proprietary PH1 payload, a spliceosome modulator designed to disrupt RNA splicing within cancer cells, induce tumor-specific cell death, and activate both the innate and adaptive immune systems. Akari's lead product candidate is AKTX-101, a TROP2-targeting ADC delivering the PH1 payload directly into tumors. The company is also developing AKTX-102, an ADC candidate targeting CEACAM5.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Shifting the company's core strategic focus to oncology and next-generation antibody-drug conjugates (ADCs) powered by the proprietary PH1 RNA-splicing payload platform, following the Peak Bio merger.
Expected impact: Establishment of a highly differentiated ADC pipeline targeting difficult-to-treat solid tumors.
Advancing lead candidate AKTX-101 (a TROP2-targeting ADC) through GLP toxicology, CMC, and pre-filing activities to support clinical readiness.
Expected impact: Transitioning Akari into a clinical-stage oncology company.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
An all-stock merger of equals to combine Akari's inflammatory disease pipeline with Peak Bio's innovative ADC toolkit and proprietary PH1 RNA-splicing payload platform, creating a combined entity focused on oncology and immunotherapy.
Financial impact: Remedied Nasdaq shareholder equity deficiency post-merger, but led to significant asset write-downs and increased R&D expenses.
Strategic Partnerships
High. Validates Akari's PH1 spliceosome-modulating payload platform and provides comprehensive CDMO services to accelerate the development, CMC, and manufacturing of AKTX-101 toward its IND filing and Phase 1 trials.
Terms: Terms not fully disclosed, but structured to reduce execution risk and accelerate clinical readiness.